Lawrence J Mulligan, MSc, PhD – Expert, Author, Writer and Co-Editor, Series A, Volume Five: Pharmacological Agents in Treatment of Cardiovascular Diseases
Roles at LPBI Group:
- Co-Editor, Series A, Volume Five: Pharmacological Agents in Treatment of Cardiovascular Diseases
- Expert on Cardiovascular Disease including Heart Failure, Lipidology, ACS and HR PCI, renal/CKD, COPD and PAH
- Expert, Author, Writer (EAW) on the following Research Categories:
- Bio Instrumentation in Experimental Life Sciences Research
- Biomarkers & Medical Diagnostics
- Acute Myocardial Infarction
- Pre-clinical development
- Heart Failure
- Medical Devices
- Origins of Cardiovascular Disease
- Atherogenic Process and Pathology
- Pharmacology of Cardiovascular Disease
Lawrence J. Mulligan, PhD, FAHA
Expert in cardiovascular disease including heart failure, lipidology, ACS and HR PCI, renal/CKD, COPD and PAH
6,438,408, Implantable medical device for monitoring congestive heart failure
6,738,667, Implantable medical device for treating cardiac mechanical dysfunction by electrical stimulation
6,810,286, Stimulation for delivery of molecular therapy
6,865,419, Method and apparatus for measurement of mean pulmonary artery pressure from a ventricle in an ambulatory monitor
6,915,157, Implantable medical device for assessing heart failure state from Mechanical Pulsus Alternans
6,994,676, Method and apparatus for assessing ventricular contractile status
7,079,887, Method and apparatus for gauging cardiac status using post premature heart rate turbulence
7,130,684, Method and apparatus for improving ventricular status using the force interval relationship
7,289,850, System for enhanced cardiac function with combined PESP/NES
7,292,888, Cardiac stimulation during a refractory period
7,792,581, Method and apparatus for treating diastolic heart failure
- Developed worldwide relationships with more than 80 KOLs
- Designed and led clinical trials (>5) providing Medtronic with clinical evidence for product development, marketing resources and protection of market share.
- Managed programs containing 20 PI’s and 50 KOLs which led to 4 published studies and 7 published abstracts.
- Participated in development of 6 advisory boards supporting product development and clinical trial design.
- Assisted Medtronic Downstream Marketing in preparation of product launches (including advisory boards and development of white papers)
- Worked with Global Marketing (Sales) to prepare sales reps for competitive launches.
- Created 4 educational programs for targeted Medtronic and customer audiences.
- Experience in cath-lab (12 years) and surgical OR (5) enviroments.
- Partnered with 10 physician customers to gather information to support critical initiatives.
- Led group that published 4 studies (cited 80 x) supporting product features and 13 (cited 210 x) pre-clinical studies that supported fundamental and applied research.
- Awarded 13 patents.
- Led group that developed an innovative leadership and engagement program.
March 2016 – October 2016
Sr Scientific Affairs Manager
- Responsible for the management of Investigator Initiated Program
- KOL development of target physicians including cardiologists, emergency room physicians, as well as those who specialize in heart failure
- MSL duties include both reactive interactions as well as disease state conversations focused on the use of Roche Diagnostics’ assays for evaluation of Acute Coronary Syndrome and Heart Failure
August 2015 – February 2016
- Created a clinical evidence and competitive landscape review for a German heart failure startup company
- The review included a synopsis of all previous clinical publications focused on devices for the treatment of heart failure and evaluation of new therapies for heart failure
Amgen (on contract via in Ventiv Health Solutions)
March 2015 – August 2015
Regional Medical Liaison
- Responsible for supporting the Cardiovascular Therapeutic Area, with primary support for Corlanor (ivabradine), a hyperpolarization-activated cyclic nucleotide-gated channel blocker for the treatment of Chronic Heart Failure
- Responsible for providing secondary support for Repatha (evolocumab), a PCSK9 Inhibitor for the treatment of hyperlipidemia. Support of evolocumab was prior to FDA approval and was primarily disease state education
- Met with Cardiologists and Heart Failure customers to conduct proactive, reactive and disease state conversations.
Respiratory Dyspnea Clinic (Brigham and Woman’s Hospital)
December 2014 – March 2015
- Under the direction of Dr David Systrom, worked as a consultant for Shape Medical Systems, a cardio-pulmonary assessment equipment manufacturer.
- Responsible for evaluation of patient data from pulmonary function testing and Level III CPX testing with the goal to determine if the Shape Medical Systems’ propietary clinical variable provided accurate assessment of clinic patients
April 2013 – May 2014
Director of Clinical Affairs
- Responsible for the creation and development of PROTECT clinical trials manuscripts in the study of their product in use for Percutaneous Coronary Intervention procedure
- Responsible for the development of regulatory/PMA literature review for submission to FDA to extend labelling options
- Managed Investigator Initiated Research Program
April 2012 – March 2013
- Responsible for providing consultative support for 4 medical device client companies including three startup companies and one company in early development of research focused on cardiac diseases
- Responsibilities including development of clinical trial and business plans, clinical research evidence and educational training material
Medtronic, Inc-Therapy Delivery Division
January 1999 – April 2012
Senior Principal Scientist, Technical Fellow, Medical Affairs Liaison
June 2004 – April 2012
Principal Clinical Study Manager
December 2002 – June 2004
RESOLV-MI Clinical Trial, Heart Failure Management.
January 1999 – December 2002
Pre-clinical heart failure research
B.S. Business Administration, 1981
Texas A&M University, 1988
M.S. Exercise Physiology
Texas A&M University, College of Veterinary Medicine
Ph.D Cardiac and Systems Physiology, 1991
Postgraduate Training and Fellowship Appointments:
1991-1993: NIH Post-doc Fellow Univ Texas Health Science Center at San Antonio, Department of
University of Notre Dame
Executive Leadership Certificate Program, 2010-11
Deborah Heart and Lung Center, 1994-1998
Assistant Professor, Senior Research Associate, pre-clinical activity
University of Pennsylvania, 1993-1994
Assistant Professor of Radiologic Science and Physiology, pre-clinical activity
Post doctoral fellow and Clinical Instructor, pre-clinical activity
2002-present: Adjunct Professor, North Dakota State University, Dept of Computer and EE;
2009-12: Adjunct Professor, Texas A&M, Dept of Biomedical Engineering;
2007-2012: Adjunct Professor, University of California at San Diego, Dept of Biomedical Engineering
- Awarded “Fellow of the American Heart Association” title, July 2010
- Awarded Medtronic top technical title “Technical Fellow”, October 2010
(this is the top award for individuals in the technical track (total number in MDT, 225)
Bose A, Kandala J, Upadhyay G, Ahmado I,Altman R, Riedl L, Mulligan LJ, Singh J. Impact of myocardial viability and left ventricular lead location on clinical outcome in cardiac resynchronization therapy recipients with ischemic cardiomyopathy. J Cardiovasc Electrophysiol. 2014 May;25(5):507-13
Leyva, F, Foley, P, Mulligan, LJ, Patel, K, Prasad, S, Stegemann, B, Smith, M. Mid-wall fibrosis as a
predictor of mortality and morbidity after cardiac resynchronization therapy in patients with non-
ischemic cardiomyopathy. J Am Coll Cardiol. 2012 Oct 23;60(17):1659-67
Nazzal CM, Mulligan LJ, Criscione JC. Efficient characterization of inhomogeneity in contraction strain
pattern. Biomech Model Mechanobiol. 2012 May;11(5):585-93
Howard EJ, Covell JW, Mulligan LJ, McCulloch AD, Omens JH, Kerckhoffs RC. Improvement in pump
function with endocardial biventricular pacing increases with activation time at the left ventricular
pacing site in failing canine hearts. Am J Physiol Heart Circ Physiol. 2011 Oct;301(4):H1447-55.
Kerckhoffs RC, Omens JH, McCulloch AD, Mulligan LJ. Ventricular dilation and electrical dyssynchrony
synergistically increase regional mechanical nonuniformity but not mechanical dyssynchrony: a computational model. Circ Heart Fail. 2010 Jul;3(4):528-36.
Merchant FM, Heist EK, Nandigam KV, Mulligan LJ, Blendea D, Riedl L, McCarty D, Orencole M, Picard
MH, Ruskin JN, Singh JP. Interlead distance and left ventricular lead electrical delay predict reverse
remodeling during cardiac resynchronization therapy. Pacing Clin Electrophysiol. 2010 May;33(5):575-82.
Black A, Ewert D, Mulligan LJ. Decay of postextrasystolic potentiation in the left and right ventricles of
intact canine hearts. Conf Proc IEEE Eng Med Biol Soc. 2009;:2904-6.
Kerckhoffs RC, Campbell SG, Flaim SN, Howard EJ, Sierra-Aguado J, Mulligan LJ, McCulloch AD. Multi
scale modeling of excitation-contraction coupling in the normal and failing heart. Conf Proc IEEE
Eng Med Biol Soc. 2009;2009:4281-2.
Mills RW, Cornelussen RN, Mulligan LJ, Strik M, Rademakers LM, Skadsberg ND, van Hunnik A, Kuiper
M, Lampert A, Delhaas T, Prinzen FW. Left ventricular septal and left ventricular apical pacing
chronically maintain cardiac contractile coordination, pump function and efficiency. Circ Arrhythm
Electrophysiol. 2009 Oct;2(5):571-9
Campbell SG, Howard E, Aguado-Sierra J, Coppola BA, Omens JH, Mulligan LJ Effect of transmurally
heterogeneous myocyte excitation-contraction coupling on canine left ventricular electromechanics.
Exp Physiol. 2009 May;94(5):541-52.
Kerckhoffs RC, McCulloch AD, Omens JH, Mulligan LJ. Effects of biventricular pacing and scar size in a
computational model of the failing heart with left bundle branch block. Med Image Anal. April 2009
Kerckhoffs RC, Narayan SM, Omens JH, Mulligan LJ, McCulloch AD. Computational modeling for
bedside application. Heart Fail Clin. 2008 Jul;4(3):371-8.
Kerckhoff, R Lumens, J, Vernooy, K Omens, JH, Mulligan, LJ, Delhaas, T, Arts, T, McCulloch, AD.
Cardiac resynchronization: Insight from experimental and computational models. Prog Biophys Mol Biol. 2008 Jun-Jul;97(2-3):543-61.
Handahl, S, Ripplinger, C., Skadsberg, N Iazzu, P, Mulligan, LJ. Effects of Pacing Rate on
Mechanical Restitution within the In Vivo Canine Heart: Study of the Force-Frequency Relationship. Cardiovasc Eng. 2007 Sep;7(3):89-96
Ahlberg, S, Hamlen, R, Ewert, D, Iaizzo, P, Mulligan, LJ. Novel Means to Monitor Cardiac
Performance: The Impact of the Force-frequency and Force-interval Relationships on
Recirculation Fraction and Potentiation Ratio. Cardiovasc Eng. 2007 Mar;7(1):32-8
Ahlberg, S, Grenz, N, Ewert, D, Iaizzo, P, Mulligan, LJ. Effect of Pacing Site on Systolic Mechanical
Restitution Curves in the In Vivo Canine Model. J Cardiovasc Electrophysiol. 2007 Feb;18(2):212-7